Home › Enanta Pharmaceuticals Announces New Data Presented On Protease Inhibitor ABT-493 At The 21st Conference On Retroviruses And Opportunistic Infections (CROI)
 

Keywords :   


Enanta Pharmaceuticals Announces New Data Presented On Protease Inhibitor ABT-493 At The 21st Conference On Retroviruses And Opportunistic Infections (CROI)

2014-03-05 04:59:35| drugdiscoveryonline Home Page

Enanta Pharmaceuticals, Inc., a research and development-focused biotechnology company dedicated to creating small molecule drugs in the infectious disease field, recently announced that new in vitro data on ABT-493, a potent NS3/4 protease inhibitor, was presented today during a poster session at the 21st Conference on Retroviruses and Opportunistic Infections (CROI) in Boston

Tags: data presented conference 21st

Category:Biotechnology and Pharmaceuticals

Latest from this category

All news
»
05.07Tropical Storm Beryl Storm Surge Watch/Warning Map
05.07Tropical Storm Beryl Graphics
05.07Tropical Storm Beryl Forecast Discussion Number 29
05.07Tropical Storm Beryl Wind Speed Probabilities Number 29
05.07Tropical Storm Beryl Forecast Advisory Number 29
05.07Tropical Storm Beryl Public Advisory Number 29
05.07Summary for Tropical Storm Beryl (AT2/AL022024)
05.07Tropical Depression Aletta Graphics
More »